KPV
KPV is a peptide, indexed here under Tissue repair peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Tissue repair peptides |
| CAS registry number | 67727-97-3[1] |
| PubChem CID | 125672[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C16H30N4O4[1] |
| Molecular weight | 342.43 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, residues 11 to 13, with the sequence lysine-proline-valine. A 1984 Peptides paper reports its effect on fever in the rabbit, a 1991 Peptides paper reports anti-inflammatory activity of analogues with altered stereochemistry, a 2003 Journal of Pharmacology and Experimental Therapeutics paper dissects the anti-inflammatory effect of the core and C-terminal alpha-MSH peptides, and a 2004 Journal of Investigative Dermatology paper reports signalling in human keratinocytes.
The later literature is intestinal. A 2008 Gastroenterology paper reports PepT1-mediated uptake of the tripeptide and reduced intestinal inflammation in its model, a 2008 Inflammatory Bowel Diseases paper reports anti-inflammatory potential in murine models, a 2016 Cellular and Molecular Gastroenterology and Hepatology paper reports the role of PepT1 in colitis-associated cancer, and 2017 Molecular Therapy, 2021 Biomaterials Science and 2022 Acta Biomaterialia papers report nanoparticle and hydrogel delivery in colitis models. A 2006 Experimental Eye Research paper reports corneal epithelial wound healing endpoints and the role of nitric oxide.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
The C-terminal tripeptide of alpha-MSH; the retrieved records report anti-inflammatory activity and PepT1-mediated uptake in intestinal epithelium.
[7, 8]Stated in the titles of the cited 2008 Gastroenterology and 2008 Inflammatory Bowel Diseases papers.
Targets named in the cited records: PepT1 transporter, alpha-MSH derived anti-inflammatory signalling.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
KPV appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- Lys-Pro-Val
- alpha-MSH 11-13
- KPV peptide
Where this page sits
Research records
Cited research records for KPV, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include KPV
Compounds indexed next to it
- BPC-157 — Tissue repair peptides
- LL-37 — Tissue repair peptides
- Larazotide — Tissue repair peptides
Named targets in the cited records
Class page: Tissue repair peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for KPV?
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, residues 11 to 13, with the sequence lysine-proline-valine. A 1984 Peptides paper reports its effect on fever in the rabbit, a 1991 Peptides paper reports anti-inflammatory activity of analogues with altered stereochemistry, a 2003 Journal of Pharmacology and Experimental Therapeutics paper dissects the anti-inflammatory effect of the core and C-terminal alpha-MSH peptides, and a 2004 Journal of Investigative Dermatology paper reports signalling in human keratinocytes.
Which class is KPV indexed under?
KPV is indexed under Tissue repair peptides. This grouping covers peptides whose retrieved research literature is predominantly concerned with tissue repair endpoints in laboratory and animal models, rather than a single shared receptor.
What does the FDA application register show for KPV?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 125672, Msh (11-13). PubChem, National Library of Medicine (2026). pubchem:125672
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:kpv
- Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides (1984). pmid:6333677
- Anti-inflammatory activity of alpha-MSH(11-13) analogs: influences of alteration in stereochemistry. Peptides (1991). pmid:1788140
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. The Journal of pharmacology and experimental therapeutics (2003). pmid:12750433
- alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. The Journal of investigative dermatology (2004). pmid:15102092
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). pmid:18061177
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases (2008). pmid:18092346
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and molecular gastroenterology and hepatology (2016). pmid:27458604
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy (2017). pmid:28143741
- <i>In situ</i> mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomaterials science (2021). pmid:34846053
- A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta biomaterialia (2022). pmid:35245681
- Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Experimental eye research (2006). pmid:16965771
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.